Showing 2683 results
- https://www.novartis.com/news/media-releases/novartis-plans-petition-us-supreme-court-uphold-validity-gilenya-fingolimod-dosing-regimen-patentAd hoc announcement pursuant to Art. 53 LR Basel, 21 September, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied its…
- https://www.novartis.com/news/media-releases/sandoz-announces-further-progress-its-biosimilar-pipeline-release-positive-results-denosumab-integrated-phase-iiii-clinical-trialROSALIA study met primary endpoints, confirming proposed biosimilar denosumab matches reference product in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in…
- https://www.novartis.com/news/media-releases/novartis-statement-regarding-competition-authority-investigation-assertion-patentCompany confident to clarify legitimacy of its position and fully cooperating with authoritiesBasel, September 15, 2022 — Novartis today confirms that it has been contacted by the Swiss Competition…
- https://www.novartis.com/news/media-releases/novartis-invests-early-technical-development-capabilities-next-generation-biotherapeuticsMulti-year investment of USD 300m will create integrated scientific environment to deliver on increasing growth and diversity of biotherapeutics portfolio Enhanced capacity and processes expected to…
- https://www.novartis.com/news/media-releases/novartis-announces-tislelizumab-demonstrated-efficacy-and-tolerability-first-line-advanced-liver-cancer-phase-iii-trialRATIONALE 301 trial met its objective at final analysis, demonstrating non-inferior overall survival (OS) for tislelizumab (median OS: 15.9 months) versus sorafenib (median OS: 14.1 months) in…
- https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-clinically-meaningful-symptom-improvements-patients-hidradenitis-suppurativa-pivotal-phase-iii-trialsResults from two parallel trials show Cosentyx® (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa (HS) signs and…
- https://www.novartis.com/news/media-releases/novartis-kisqali-adds-one-more-year-survival-benefit-broadest-set-patients-including-those-aggressive-hrher2-advanced-breast-cancerNew large pooled exploratory analysis from MONALEESA-2, -3 and -7 reinforces unparalleled overall survival (OS) benefit of Kisqali plus ET compared to ET alone, in HR+/HER2- aBC patients with…
- https://www.novartis.com/news/media-releases/novartis-highlights-depth-immunology-pipeline-novel-data-key-upcoming-international-congressesPivotal results for efficacy and safety of Cosentyx® (secukinumab) in hidradenitis suppurativa from Phase III SUNSHINE and SUNRISE trials to be debuted as late-breaker at European Academy of…
- https://www.novartis.com/news/media-releases/novartis-appoints-fiona-marshall-phd-president-novartis-institutes-biomedical-research-jay-bradner-md-steps-down-from-executive-committee-novartisAfter seven years as President of NIBR and a member of the ECN, Dr. Bradner will pursue a next chapter of scientific contribution and leadership outside of NovartisBuilding on NIBR foundation, Dr.…
- https://www.novartis.com/news/media-releases/novartis-presents-new-data-breast-and-prostate-cancer-esmoOverall survival results from pooled exploratory analysis of MONALEESA trials in patients with aggressive HR+/HER2- advanced breast cancer treated with Kisqali®Data from VISION study reporting…